Clinical Applications of Recombinant Human Granulocyte Colony-Stimulating Factor in Reproductive Medicine: Expert Consensus
Journal Title: Diseases & Research - Year 2023, Vol 3, Issue 1
Abstract
Recombinant human granulocyte colony-stimulating factor (rhG-CSF) is primarily indicated for neutropenia caused by various etiologies in clinical practice. Recently, it has been shown to have some therapeutic effects and be safe for mother and child in some clinical research and treatment of reproductive diseases. However, until now, there is currently no authoritative expert consensus and guidelines published. To standardize the research and rational application of rhG-CSF in reproductive medicine-related fields, the Committee on Reproductive Immunity of the China Association for Promotion of Health Science and Technology (the Committee) organized experts from relevant disciplines to formulate the Expert Consensus, which is based on the latest international basic study, clinical research evidence, and the national situation of China. According to evidence-based data, recommendations were established on the applicable population, medication methods, and timing of discontinuation of rhG-CSF in reproductive medicine. It is recommended that rhG-CSF could be applied in patients with thin endometrium, which was ineffective to standard treatments, in unexplained recurrent spontaneous abortion (RSA), in unexplained recurrent implantation failure (RIF), and could attempt to be applied in unexplained RSA with the slow rise of human chorionic gonadotropin and embryo growth retardation. After the patient signs the super instruction for medication and treatment informed consent form, rhG-CSF can only be used for patients with thin endometrium, unexplained recurrent miscarriage, unexplained repeated embryo implantation failure, slow rise of human chorionic gonadotropin. Comprehensive communication between gynecologists and obstetricians and patients before therapy is essential according to that the rhG-CSF treatment would be inefficient when a genetic abnormality, embryo abnormality, heterotopic pregnancy and other unknown disorder exist.
Authors and Affiliations
Jianming Chen, Yazhong Ji, Zhaohui Zhang
Keywords
Related Articles
- EP ID EP740146
- DOI 10.54457/DR.202301008
- Views 24
- Downloads 0
Oral Versus Intravenous Chemotherapy in COVID-19 Epidemic
The novel coronavirus has a significant impact on the routine clinical practice for cancer patients in China since De-cember 2019. During the epidemic in mainland China, especially Wuhan, the intravenous chemotherapies o...
Successful Treatment with CAR- T Cells in a Patient with Immune Thrombocytopenia Associated with Castleman Disease
Multicentric Castleman disease (MCD), a rare lymphoproliferative disorder of incompletely understood etiology, is manifested as enlarged multiple lymph node and multiple organs involvement. The best therapeutic option fo...
Hepatic Paragonimiasis: A Case Report and Literature Review
Paragonimiasis is a parasitic disease caused by paragnonimus, which primarily caused infection in the lung, and ectopic infection was less common. Ectopic paragonimiasis are more likely to be misdiagnosed as malignancy o...
Plasma Exchange to Treat Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome after Anti-CD19 Chimeric Antigen Receptor-T Cell Infusion: A Case Report
Adoptive cell immunotherapy with chimeric antigen receptor-T (CAR-T) cells has shown remarkable clinical out-comes. However, cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICA...
Salvage Therapy with Gilteritinib Plus Venetoclax for FLT3-ITD-Positive AML: A Case Report and Literature Review
FMS-like tyrosine kinase 3 (FLT3) mutations occur in around 30% of patients in acute myeloid leukemia (AML), and are generally associated with unfavorable outcomes. Gilteritinib is a highly specific second-generation cla...